St. Jude Medical, Inc. STJ, a medical device company, today
announced results from its RESPECT trial, which studied the AMPLATZER™
PFO Occluder in the prevention of recurrent cryptogenic stroke. Evidence
presented at a late breaking trial session during the 24th
Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific
symposium, sponsored by the Cardiovascular Research Foundation, shows
that the primary analysis was not statistically significant but trended
towards superiority, while additional analyses demonstrated superiority.
Stroke risk reduction was observed across the totality of analyses with
rates ranging from 46.6 percent - 72.7 percent.
According to the World Health Organization (WHO), an estimated 15
million strokes occur worldwide each year. In 2010, stroke cost the
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in